NF1 and gastrointestinal stromal tumor: The remaining patients in this group (3/98; 3%) were sarcoma (GIST) patients with NF1 mutations indicating they should not receive imatinib, or NSCLC patients with EGFR T790M mutations (3/98; 3%) indicating resistance to first and second generation EGFR TKIs.